<DOC>
	<DOCNO>NCT00144183</DOCNO>
	<brief_summary>To determine whether regimen single dose nevirapine combine either 4 7 day Combivir® , compare regimen single dose nevirapine , prevention mother child transmission reduce rate development drug resistant mutation HIV-1 , HIV-1 infect pregnant woman , receive antiretroviral therapy previously .</brief_summary>
	<brief_title>A Study Single Dose Nevirapine ( NVP ) Combined With Combivir® Prevention Mother Child Transmission ( pMTCT ) - Treatment Options Preservation Study ( TOPS )</brief_title>
	<detailed_description>An open-label , randomise , multicentre study determine whether regimen single dose nevirapine combine either 4 7 day Combivir , compare regimen single dose nevirapine , prevention mother child transmission reduce rate development drug resistant mutation HIV-1 , HIV-1 infect pregnant woman , receive antiretroviral therapy previously . An interim analysis first 61 patient show clinical statistical difference exists occurrence HIV-1 NNRTI resistant mutation single dose nevirapine arm ( 50 % ) two combination arm ( 9 % ) . These finding partially answer objective outline initial objective . Consequently enrolment onto single dose nevirapine arm terminate . The objective trial modify compare whether either 4 7 day combination ZDV+3TC nevirapine would result significant reduction incidence nevirapine resistance . Study Hypothesis : Evaluations HIV-1 resistance pattern trial pMTCT demonstrate nevirapine resistant HIV-1 isolates approximately 15-20 % mother 4-6 week receive either single two dose 200mg nevirapine regimen . Although ability detect genotypic mutation decrease 0 % 18 month , clear whether resistance clinically significant . ( HIVNET 012 ) . Empirically would seem useful develop strategy diminish emergence early resistance , therefore study propose evaluate whether effect 4 7 day 3TC+ ZDV add single dose nevirapine regimen prevention MTCT prevent emergence resistance nevirapine . Comparison ( ) : ACTG 076 , Thai , PETRA , HIVNET 006/012 , SAINT</detailed_description>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Nevirapine</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<mesh_term>Lamivudine , zidovudine drug combination</mesh_term>
	<criteria>Pregnant woman identify antenatal clinic 34 week gestation antiretroviral drug naive . Mothers document positive HIV Rapid test confirm detectable HI V1 RNA PCR ( viral load ) . Mother screen viral load &gt; 2000 RNA copies/mL . Mothers , opinion investigator , rely return infant postnatal visit . Mothers receive antiretroviral drug previously . Clinical suspicion intrauterine foetal death Unwillingness inability reasonably comply protocol requirement . Use investigational product pregnancy dura tion study period . Patients recent history pancreatitis peripheral neuropathy . Patients renal failure require dialysis . Patients evidence hepatic dysfunction measure total bilirubin &gt; 2.5 time ULN AST/ALT &gt; 5 time ULN screen visit . Patients one follow additional laboratory abnormality screen : Haemoglobin concentration &lt; 7.5 g/dl . Neutrophil count &lt; 750 cells/mm3 . Platelet count &lt; 75,000 cells/mm3 . Serum amylase &gt; 2 x ULN . recent history ( pregnancy ) drug abuse alcoholism . Mothers undergo elective caesarean section . If know prior delivery , mother foetuses anomaly incompatible life .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
</DOC>